Daiichi Sankyo announced that the independent data monitoring committee of the METIV-Hepatocellular cancer (HCC) study conducted a planned interim assessment […]
The post Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma appeared first on .
